Ovid Therapeutics Inc. - Common Stock (OVID)

Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.

Ovid Therapeutics announces CEO succession plan and key pipeline progress for epilepsy drug OV329 and KCC2 activators, backed by a strong cash position.

Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

Wondering what's happening in Friday's pre-market session? Find an overview in this article.

The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.